Novartis provides safety update for Beovu

A safety review into Novartis’ new anti-VEGF drug Beovu has revealed that reported adverse events are consistent with the approved prescribing information after a group of US retinal specialists linked it to a series of vasculitis cases. Read more

Novartis pursues PBS listing for Beovu  

Novartis is working to ensure its newly-approved drug Beovu is accessible via the Pharmaceutical Benefits Scheme (PBS) at the earliest opportunity after expressing disappointment over an initial decision not to recommend it for the government-subsidised medicines program. Read more